by Jon Fleetwood, Jon Fleetwood: New patients continued to be recruited for 6 months after the futility boundary was crossed, Public European trial records show. BioNTech has terminated a Phase 2 trial of its experimental mRNA cancer shot autogene cevumeran (BNT122) after an independent monitoring board found an imbalance in overall survival, with development partner Genentech confirming there were […]